

# The effects of a prebiotic supplement on exercise induced asthma and markers of airway inflammation

<b>Submission date</b> 04/01/2016	<b>Recruitment status</b> No longer recruiting	<input type="checkbox"/> Prospectively registered <input type="checkbox"/> Protocol
<b>Registration date</b> 06/01/2016	<b>Overall study status</b> Completed	<input type="checkbox"/> Statistical analysis plan <input type="checkbox"/> Results
<b>Last Edited</b> 27/02/2018	<b>Condition category</b> Respiratory	<input type="checkbox"/> Individual participant data <input type="checkbox"/> Record updated in last year

## Plain English summary of protocol

### Background and study aims

Asthma is a common long-term condition that affects approximately 235 million people worldwide. It can cause coughing, wheezing, tightness of the chest and breathlessness. It is caused by inflammation of the small tubes that carry air in and out of the lungs (the bronchi). When a sufferer comes across something that then irritates their lungs (a trigger), the airways narrow causing the symptoms of the disease. Common asthma triggers include allergies (to for example, house dust mites or animal fur) and viral infections. Exercise-induced asthma occurs when the airways narrow during and/or after exercise. It is referred to as exercise-induced bronchoconstriction (EIB). It is very common in asthma sufferers and sports men and women. Asthma can be well-controlled with treatments such as inhaled corticosteroids and short- and long-acting Beta2-agonists. However, these therapies do not cure the condition or prevent disease progression. Many patients also don't take the treatment as they should. Treatments that help prevent the inflammation of the bronchi and the immune response to triggers, without causing harmful side effects, would therefore be of benefit. There is evidence to suggest that the gut microbiota (trillions of live bacteria that live in the gut) has a substantial influence on the immune system and the allergic reaction. Prebiotics have been shown to increase the growth and/or activity of beneficial bacteria in the gut and thereby may protect against and reduce the severity of allergic, and airway inflammatory diseases. Prebiotic Bimuno-galactooligosaccharides (B-GOS) are especially potent in selectively increasing the growth and/or activity of bifidobacteria (a common beneficial bacteria found in the gut). The effects of B-GOS on asthma in humans, however, is not known. Therefore, the aim of this study was to see if prebiotic supplementation in adults with exercise-induced asthma would reduce the severity of bronchoconstriction (narrowing of the airways) and whether it also helps reduce inflammation of the airways.

### Who can participate?

Adults either diagnosed with asthma, or known not to have asthma.

### What does the study involve?

All participants (whether asthma sufferers or not) are randomly allocated into one of two

groups. Those in group 1 are given B-GOS to take every day for 3 weeks (21 days). Those in group 2 are given a placebo (a dummy pill) to take every day for three weeks. All participants then resume their normal diet for two weeks before taking the other treatment for an additional 21 days (this means that all participants eventually take both treatments). Each participant attends a laboratory for lung function tests and blood samples to test for evidence of airway inflammation before they start each treatment and then 21 days later (when that treatment ends).

What are the possible benefits and risks of participating?

Participants may benefit from gaining a greater understanding into managing and controlling their asthma and exercise induced asthma. Risks include some discomfort when taking blood samples, and some participants might find that the tests trigger off their asthma symptoms. All asthmatic participants will have their own clinically prescribed medication ( $\beta$ 2-agonist) for treating episodes of asthma and EIB.

Where is the study run from?

Nottingham Trent University (UK)

When is study starting and how long is it expected to run for?

December 2012 to March 2014.

Who is funding the study?

Nottingham Trent University (UK)

Who is the main contact?

Dr Neil Williams

Neil.Williams@ntu.ac.uk

## Contact information

### Type(s)

Scientific

### Contact name

Dr Neil Williams

### ORCID ID

<http://orcid.org/0000-0002-2607-4572>

### Contact details

Nottingham Trent University

Department of Sport Science

School of Science and Technology

Clifton Campus

Nottingham

United Kingdom

NG118NS

+44 (0)115 8483325

neil.williams@ntu.ac.uk

# Additional identifiers

EudraCT/CTIS number

IRAS number

ClinicalTrials.gov number

Secondary identifying numbers

N/A

## Study information

### Scientific Title

The effects of a prebiotic galactooligosaccharide mixture (B-GOS) on the severity of hyperpnea-induced bronchoconstriction and airway inflammation in adults with asthma

### Study objectives

It is hypothesised that a prebiotic galacto-oligosaccharide mixture (B-GOS) will reduce the severity of hyperpnea-induced bronchoconstriction and airway inflammation in adults with asthma.

### Ethics approval required

Old ethics approval format

### Ethics approval(s)

Nottingham Trent University Human Ethics Committee, 27/11/2012, ref: 229

### Study design

Single centre randomised double-blind placebo-controlled cross-over controlled study

### Primary study design

Interventional

### Secondary study design

Randomised controlled trial

### Study setting(s)

Not specified

### Study type(s)

Treatment

### Participant information sheet

Not available in web format, please use contact details to request a participant information sheet

### Health condition(s) or problem(s) studied

Exercise induced asthma

## **Interventions**

Participants were randomly assigned to receive 5.5 g.day of either galactooligosaccharide B-GOS (Bimuno) or placebo (maltodextrin) (Clasado Ltd, Milton Keynes, UK) for 3 weeks.

Participants then followed a 2 week washout period (normal diet) before commencing the alternative supplement for the remaining 3 weeks.

## **Intervention Type**

Supplement

## **Primary outcome measure**

Pulmonary function data (forced expiratory volume in 1 second, forced vital capacity, and peak expiratory flow) at baseline and in response to the eucapnic voluntary hyperpnoea test (in both asthmatic and non-asthmatic groups).

Data was collected at day 0 and day 21.

## **Secondary outcome measures**

1. Baseline and post eucapnic voluntary hyperpnoea (EVH) blood sampling for markers of airway inflammation (chemokines CCL11 and CCL17; tumour necrosis factor-alpha (TNF- $\alpha$ ); c-reactive protein; and immunoglobulin E) – (collected in both asthmatic and non-asthmatic groups)
2. Fraction of exhaled nitric oxide (collected in asthmatic group only)

Serum chemokine and TNF- $\alpha$  levels were measured from blood samples taken at baseline and 15 min, 60 min and 24 h after EVH.

Data was collected at day 0 and day 21.

## **Overall study start date**

01/12/2012

## **Completion date**

03/03/2014

# **Eligibility**

## **Key inclusion criteria**

1. Body mass index (BMI) 20-25 KG.M-2
2. Physically active 3 or more times a week , with each exercise session lasting at least 45 min
3. Non-smoker
4. Non-vegetarian or vegan
5. Asthma sufferers must have own clinically prescribed medication
6. Asthma sufferers must have a GP diagnosis

## **Participant type(s)**

Healthy volunteer

## **Age group**

Adult

**Sex**

Both

**Target number of participants**

12 asthma patients with exercise induced asthma, and 12 controls with no history of asthma or exercise induced asthma

**Key exclusion criteria**

1. Predicted forced expiratory volume in 1 second (FEV1) less than 65%
2. Previously diagnosed with COPD, emphysema, chronic bronchitis or similar respiratory illness
3. Previously admitted to hospital for asthma or other breathing difficulties
4. Asthma exacerbation within the last month (Course of steroids, or hospital visit)
5. History of heart failure, pulmonary hypertension, embolism, or other pulmonary heart disease
6. History of recurrent chest infections
7. Smoker
8. Acute infection within the last four weeks
9. Major operation within the past four months
10. Have a history of taking  $\omega$ -3 PUFA supplements or supplements with antioxidants above recommended intake, or consume more than three fatty fish meals per week
11. Take a daily dose of aspirin or other NSAIDs
12. Currently taking a daily dose of anti-histamine
13. Currently taking long term asthma maintenance medications – corticosteroids, and leukotriene modifiers that you could not refrain from taking for 4 days prior to laboratory session

**Date of first enrolment**

02/12/2012

**Date of final enrolment**

01/12/2013

**Locations****Countries of recruitment**

England

United Kingdom

**Study participating centre**

**Nottingham Trent University**

Nottingham

United Kingdom

NG11 8NS

**Sponsor information**

**Organisation**

Nottingham Trent University

**Sponsor details**

Nottingham Trent University  
Department of Sport Science  
School of Science and Technology  
Clifton Campus  
Nottingham  
England  
United Kingdom  
NG11 8NS

**Sponsor type**

University/education

**ROR**

<https://ror.org/04xyxjd90>

**Funder(s)****Funder type**

University/education

**Funder Name**

Nottingham Trent University

**Results and Publications****Publication and dissemination plan**

Publication in a peer-reviewed journal

**Intention to publish date**

01/01/2016

**Individual participant data (IPD) sharing plan****IPD sharing plan summary**

Available on request